Johnson Matthey announced a strategic manufacturing partnership for the large-scale production of the drug-linker used in Immunomedics’ lead antibody-drug conjugate. The antibody-drug conjugate, sacituzumab govitecan, is a treatment for patients with metastatic triple-negative breast cancer, currently under priority review by the FDA for accelerated approval. If approved, sacituzumab govitecan would be the first therapy approved for this patient group. The drug-linker CL2A-SN-38 is...